EFFECT OF PROBUCOL TREATMENT ON THE SUSCEPTIBILITY OF LOW-DENSITY-LIPOPROTEIN ISOLATED FROM HYPERCHOLESTEROLEMIC PATIENTS TO BECOME OXIDATIVELY MODIFIED INVITRO

被引:53
作者
REGNSTROM, J [1 ]
WALLDIUS, G [1 ]
CARLSON, LA [1 ]
NILSSON, J [1 ]
机构
[1] KAROLINSKA INST,DEPT MED,S-10401 STOCKHOLM 60,SWEDEN
关键词
Hypercholesterolemic patients; LDL receptor; Macrophages; Oxidatively modified LDL; Probucol;
D O I
10.1016/0021-9150(90)90142-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lipid accumulation in monocyte-originated macrophages in the subendothelial space is an important characteristic of atherosclerotic lesions. Several lines of evidence have indicated that this accumulation occurs as a result of lipid peroxidation. In the present study the ability of probucol to prevent oxidation of low density lipoprotein (LDL) was investigated in 20 hypercholesterolemic individuals taking part in the Probucol Quantitative Regression Swedish Trial (PQRST). The effect of Cu2+-induced oxidation of LDL on degradation by macrophages, binding to LDL receptors on fibroblasts and LDL TBARS content was analysed. With LDL isolated from patients on diet alone oxidation led to a 44.3% decreased binding to fibroblasts (P < 0.001), a ninefold increased uptake in macrophages (P < 0.001) and a twentyfold increase in TBARS content (P < 0.001) as compared to native LDL. These values were essentially the same during treatment with cholestyramine alone. However, during treatment with probucol plus cholestyramine exposure of LDL to Cu2+ resulted in an increase in TBARS which was less than 50% (P < 0.02) of that observed during the other two treatment periods. Furthermore, probucol treatment abolished more than 70% of the decrease in B,E receptor binding to fibroblasts (P < 0.05) and more than 90% of the increased degradation by macrophages (P < 0.001) of Cu2+ oxidatively modified LDL. © 1990.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 33 条
[1]   MULTIPLE RECEPTORS FOR MODIFIED LOW-DENSITY LIPOPROTEINS IN MOUSE PERITONEAL-MACROPHAGES - DIFFERENT UPTAKE MECHANISMS FOR ACETYLATED AND OXIDIZED LOW-DENSITY LIPOPROTEINS [J].
ARAI, H ;
KITA, T ;
YOKODE, M ;
NARUMIYA, S ;
KAWAI, C .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 159 (03) :1375-1382
[2]   THE SCAVENGER CELL PATHWAY FOR LIPOPROTEIN DEGRADATION - SPECIFICITY OF THE BINDING-SITE THAT MEDIATES THE UPTAKE OF NEGATIVELY-CHARGED LDL BY MACROPHAGES [J].
BROWN, MS ;
BASU, SK ;
FALCK, JR ;
HO, YK ;
GOLDSTEIN, JL .
JOURNAL OF SUPRAMOLECULAR STRUCTURE, 1980, 13 (01) :67-81
[3]   REGULATION OF ACTIVITY OF LOW-DENSITY LIPOPROTEIN RECEPTOR IN HUMAN FIBROBLASTS [J].
BROWN, MS ;
GOLDSTEIN, JL .
CELL, 1975, 6 (03) :307-316
[4]   LIPOPROTEIN METABOLISM IN THE MACROPHAGE - IMPLICATIONS FOR CHOLESTEROL DEPOSITION IN ATHEROSCLEROSIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1983, 52 :223-261
[5]   IDENTIFICATION OF APO-B-100 SEGMENTS MEDIATING THE INTERACTION OF LOW-DENSITY LIPOPROTEINS WITH ARTERIAL PROTEOGLYCANS [J].
CAMEJO, G ;
OLOFSSON, SO ;
LOPEZ, F ;
CARLSSON, P ;
BONDJERS, G .
ARTERIOSCLEROSIS, 1988, 8 (04) :368-377
[7]  
CARLSON K, 1973, J CLIN PATHOL S5, V26, P32
[8]   MONOCYTES AND NEUTROPHILS OXIDIZE LOW-DENSITY LIPOPROTEIN MAKING IT CYTO-TOXIC [J].
CATHCART, MK ;
MOREL, DW ;
CHISOLM, GM .
JOURNAL OF LEUKOCYTE BIOLOGY, 1985, 38 (02) :341-350
[9]  
ELSAADANI M, 1989, J LIPID RES, V30, P627
[10]   A COLORIMETRIC METHOD FOR ESTIMATING SERUM TRIGLYCERIDES [J].
FLETCHER, MJ .
CLINICA CHIMICA ACTA, 1968, 22 (03) :393-&